Why Otsuka’s $1.2bn Transcend Therapeutics buyout could reshape PTSD drug development
Find out how Otsuka’s Transcend Therapeutics acquisition could reshape rapid-acting PTSD treatment development.
Pharma & Biotech
Pharma & Biotech
Emalex Biosciences advances Tourette syndrome strategy as ecopipam delays relapse in Phase 3 trial
D1 receptor targeting may change Tourette syndrome care. Ecopipam’s Phase 3 data now face the bigger test: regulation and adoption.